ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular My

Project: Research project

Project Details

StatusActive
Effective start/end date9/7/17 → 8/31/50

Funding

  • Audentes Therapeutics, Inc.